Department of Dermatology, Hospital del Mar, Universitat Autònoma de Barcelona, pg. Marítim 25-29, ES-08003 Barcelona, Catalonia, Spain. E-mail:
Acta Derm Venereol. 2021 May 19;101(5):adv00460. doi: 10.2340/00015555-3828.
BIOMED-2 Concerted Action BMH4-CT98-3936 (BIOMED-2) PCR protocols are an important diagnostic tool in the evaluation of cutaneous lymphomas. The aim of this study was to assess the diagnostic value of the genotyping results obtained by these techniques in daily clinical practice. A total of 360 paraffin-embedded skin samples were retrospectively reviewed from 114 cutaneous T-cell lymphomas and 35 cutaneous B-cell lym-phomas. A total of 249 biopsies from 180 patients with benign lymphoid infiltrates served as controls. T-cell receptor and immunoglobulin gene rearrangements were assessed using the BIOMED-2 method. A combined T-cell receptor gamma and beta assay approach reliably distinguished cutaneous T-cell lymphomas from benign skin T-cell infiltrates (sensitivity 89.4%; specificity 81.5%). Analysis of complete immunoglobulin heavy chain rearrangements also differentiated cutaneous B-cell lymphomas from benign B-cell infiltrates (sensitivity 85.7%; specificity 82.4%). In conclusion, the full BIOMED-2 protocol is a useful aid combined with clinical, histological and immunophenotypical findings for assessment of lymphoid clonality in skin lymphoid proliferations.
BIOMED-2 协同行动 BMH4-CT98-3936(BIOMED-2)聚合酶链反应(PCR)方案是评估皮肤淋巴瘤的重要诊断工具。本研究旨在评估这些技术获得的基因分型结果在日常临床实践中的诊断价值。从 114 例皮肤 T 细胞淋巴瘤和 35 例皮肤 B 细胞淋巴瘤的 360 例石蜡包埋皮肤样本中进行了回顾性分析。249 例来自 180 例良性淋巴样浸润患者的活检作为对照。使用 BIOMED-2 方法评估 T 细胞受体和免疫球蛋白基因重排。T 细胞受体γ和β联合检测方法可靠地区分了皮肤 T 细胞淋巴瘤与良性皮肤 T 细胞浸润(敏感性 89.4%;特异性 81.5%)。完整的免疫球蛋白重链重排分析也可区分皮肤 B 细胞淋巴瘤与良性 B 细胞浸润(敏感性 85.7%;特异性 82.4%)。总之,完整的 BIOMED-2 方案是一种有用的辅助手段,结合临床、组织学和免疫表型发现,可用于评估皮肤淋巴样增生中的淋巴克隆性。